Clinical Trial Environmental Impact
CMC Ontology
Data FAIRy Bioassay Annotation
Global Substance Registration System
IDMP Ontology
In Vitro NAM Data Standards
In Vitro Pharmacology
Large Language Models in Life Sciences
NLP Use Case Database
Pharma General Ontology
Pharmacovigilance Systems and Processes Standards
Social Media Real World Evidence
Current Projects
Delivered Projects
AI / ML
Change Management
CSCS
Data Governance
FAIR
Future Labs Evolution
Microbiome-Mediated Drug Metabolism Database
Quantum Computing
UXLS
Current Communities
Delivered Communities
Delivered Projects and Communities
New Ideas
Username or Email Address
Password
Remember Me
Webinar
The Pistoia Alliance has a global mission to “lower barriers to innovation in life science R&D & healthcare.” In another in our series of Japan Outreach webinars we provide some specific examples of where its pre-competitive collaboration model of shared-risk and shared-reward can bring value.
This webinar will demonstrate how ontologies are essential to understanding the incoming data deluge for an enterprise & how they help retrieve the most relevant data for R&D efforts.
This session will explore the Pistoia Alliance’s new IDMP Ontology project and its potential global implementation approach.
Today, the hype that surrounded artificial intelligence in the previous years is largely gone, and the industry practitioners are looking for solid use cases and proof of value. Prashant Natarajan, VP of H2O.ai, and Dr. Peter Henstock, ML&AI Technical Lead Technical Lead, Pfizer, will discuss the methods for valuation of artificial intelligence investments in the pharmaceutical industry.
AutoDesigner, a De Novo Design Algorithm for Rapidly Exploring Large Chemical Space for Lead Optimization: Application to the Design and Synthesis of D-Amino Acid Oxidase Inhibitors
We have assembled a panel of experts from Scibite, Pfizer, GSK and Astrazeneca to discuss why it’s valuable to leverage the interplay of ontologies and FAIR, and what a difference it can make in R&D decision making.
This webinar covers laboratory automation and robotics and the benefits they offer in terms of quality and speed of data generation synergized with AI/ ML-powered drug discovery approaches.
During this webinar we will share some of the key challenges and opportunities organizations face today, along with some examples of Pistoia Alliance member-driven initiatives to highlight the power of pre-competitive collaboration in advancing digitalization and automation on the path towards their Lab of the Future.
In this talk our speaker, Dimitris K. Agrafiotis, Vice President, Digital, Worldwide Research, Development and Medical, Pfizer will discuss some of the common challenges and pitfalls in visualizing data and highlight a number of analytic solutions that he and his teams have developed over his 30-year career in pharmaceutical R&D, reflecting on the design, engineering, and organizational principles that underpinned their success.
The aim of this community is to accelerate the adoption of quantum computing in the pharmaceutical industry. Our most recent community survey identified the lack of relevant use cases as the biggest barrier to adoption. This session will tackle this by looking at quantum use cases from leading organizations, and include a panel discussion to explore potential next steps for the industry.
This presentation is a call to ‘put data before visualization’. We show how simple ‘spaghetti’ plots offer a useful alternative to waterfall plots, in order to understand drug effects and support decision-making in early clinical development.
At the Pistoia Alliance, we are exploring how the FAIRification of such data, along with advanced analytics including AL/ML/NLP powered systems can be used to access/share/reuse patient data from historical clinical trials.
